Sensus Healthcare, Inc. (NASDAQ:SRTS) Sees Significant Growth in Short Interest

Sensus Healthcare, Inc. (NASDAQ:SRTS) was the recipient of a significant growth in short interest in December. As of December 31st, there was short interest totalling 1,210,000 shares, a growth of 107.4% from the December 15th total of 583,500 shares. Approximately 9.2% of the company’s stock are short sold. Based on an average trading volume of 203,100 shares, the short-interest ratio is currently 6.0 days.

Institutional Inflows and Outflows

A number of large investors have recently modified their holdings of SRTS. Truvestments Capital LLC acquired a new stake in Sensus Healthcare during the third quarter worth about $32,000. XTX Topco Ltd bought a new position in shares of Sensus Healthcare during the second quarter valued at approximately $95,000. Cubist Systematic Strategies LLC acquired a new stake in shares of Sensus Healthcare during the 2nd quarter worth approximately $156,000. Acadian Asset Management LLC lifted its holdings in shares of Sensus Healthcare by 578.6% in the 2nd quarter. Acadian Asset Management LLC now owns 45,124 shares of the company’s stock worth $239,000 after purchasing an additional 38,474 shares during the last quarter. Finally, Ritholtz Wealth Management boosted its position in Sensus Healthcare by 65.3% during the 4th quarter. Ritholtz Wealth Management now owns 51,261 shares of the company’s stock valued at $355,000 after purchasing an additional 20,256 shares during the period. 25.30% of the stock is currently owned by institutional investors.

Sensus Healthcare Price Performance

SRTS traded down $0.04 during trading hours on Thursday, hitting $6.73. 136,249 shares of the stock were exchanged, compared to its average volume of 219,665. The stock has a market cap of $110.30 million, a price-to-earnings ratio of 11.81 and a beta of 1.21. The stock has a 50-day simple moving average of $7.69 and a 200-day simple moving average of $6.71. Sensus Healthcare has a 12 month low of $2.61 and a 12 month high of $9.33.

Wall Street Analysts Forecast Growth

SRTS has been the subject of several recent analyst reports. Maxim Group raised their price objective on shares of Sensus Healthcare from $12.00 to $14.00 and gave the stock a “buy” rating in a report on Friday, November 15th. HC Wainwright lifted their price target on Sensus Healthcare from $10.00 to $11.00 and gave the stock a “buy” rating in a research note on Monday, November 18th.

Sensus Healthcare Company Profile

Sensus Healthcare, Inc, a medical device company, manufactures and sells radiation therapy devices to healthcare providers worldwide. The company uses superficial radiation therapy, a low-energy X-ray technology in its portfolio of treatment devices. It offers SRT-100, a photon X-ray low energy superficial radiotherapy system that provides patients an alternative to surgery for treating non-melanoma skin cancers, including basal cell and squamous cell skin cancers, as well as other skin conditions, such as keloids; and SRT-100 Vision, which provides the user with a superficial radiation therapy-tailored treatment planning application that integrates an embedded high frequency ultrasound imaging module, volumetric tumor analysis, beam margins planning, and dosimetry parameters.